China’s Capitalmakes strategic investment of nearly USD10m in Silicon Valley nano-biotechnology company DynaBio

DynaBio, a biological nanotechnology company based in Silicon Valley in the United States, recently completed a strategic investment of nearly 10 million US dollars from China’s Capital Global Innovation Fund and well-known Silicon Valley venture capital institutions.

DynaBio, a biological nanotechnology company based in Silicon Valley in the United States, recently completed a strategic investment of nearly 10 million US dollars from China’s Capital Global Innovation Fund and well-known Silicon Valley venture capital institutions.

Proceeds from this round of financing will be used for the company’s upstream and downstream resources construction and technical research and development.

DynaBio focuses on the research and development and commercialization of nanomaterials and functions, biological nanomaterials and nanomedicine technology. It has established a bionanomaterial synthesis laboratory in California.

At present, the company has established a series of dozens of categories of biological micro-nanomaterial products, including various types of gold nanoparticles, silver nanoparticles, iron-based magnetic nanoparticles, nanoemulsions, nanopolymer carriers, intelligent magnetic response gel etc., which are widely used in areas such as cell magnetic labeling tracing, gene magnetic transfection, cell magnetic sorting, gene magnetic separation, magnetic / fluorescence immunochromatography detection, chemiluminescence detection, immunoprecipitation, MRI, contrast, ultrasound imaging, photoacoustic imaging, dark field imaging, surface-enhanced Raman detection, photothermal therapy, magnetic induction hyperthermia and others.

This round of financing was led by Sun Eng, the executive partner of the venture capital group of China’s Capital, and president of Zhongyang Medical Group. Zhongyang Medical Group is an industrial company under China’s Capital that focuses on strategic investment and operation in the field of pan-health.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/24/chinas-capitalmakes-strategic-investment-of-nearly-usd10m-in-silicon-valley-nano-biotechnology-company-dynabio/.

Leave a Reply

Your email address will not be published. Required fields are marked *